Secondary failure of lentiviral vector gene therapy in a cerebral adrenoleukodystrophy patient with an ABCD1 whole-gene deletion
Molecular Therapy · 2024
DOI: 10.1016/j.ymthe.2024.08.005 ↗Kurz gefasst
Fallbericht in der Zeitschrift Molecular Therapy, 2024. Verfasst von Troy C Lund und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Pediatric Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN, USA. Electronic address: …. Hauptthemen laut MEDLINE: Adrenoleukodystrophy, ATP Binding Cassette Transporter, Subfamily D, Member 1, Genetic Therapy, Genetic Vectors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
A 9-year-old boy with adrenoleukodystrophy due to ABCD1 whole-gene deletion was diagnosed with active cerebral adrenoleukodystrophy characterized by demyelination and gadolinium enhancement on brain MRI. He underwent hematopoietic cell transplant (HCT) with autologous CD34+ cells transduced with an ABCD1-expressing lentiviral vector (eli-cel [elivaldogene autotemcel]) as part of the ALD-104 clinical trial. Fifty days after HCT, the patient's MRI showed gadolinium resolution; the whole-blood vector copy number (VCN) was 0.666 copies/mL. Six months following HCT, an MRI showed re-emergence of gadolinium enhancement; the VCN had decreased to 0.029 copies/mL. Polyclonal antibodies to the ABCD1 gene product were detectable 9 months after transplant, showing reactivity to peroxisomes, suggesting an immune response; however, no antibody binding to human CD34+ cells could be shown. The patient underwent a successful allogeneic HCT 12 months after gene therapy with resultant gadolinium resolution, cerebral disease stabilization, and the disappearance of antibodies. The coincident VCN loss and appearance of antibody to the ABCD1 gene product is of interest, and we postulate that it is related to the patient's whole ABCD1 gene deletion. We suggest close monitoring of loss of gene therapy efficacy due to immune response in patients with full deletions who are considering gene therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Pediatric Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN, USA. Electronic address: lundx072@umn.edu.
- Department of Pediatrics, Division of Pediatric Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN, USA.
- Department of Diagnostic Radiology, University of Minnesota Medical Center, Minneapolis, MN, USA.
- bluebird bio, Cambridge, MA, USA.
Zitieren
APA
Lund, T. C., Orchard, P. J., Nascene, D. R., King, C. J., Braun, J., Thakkar, S., Durose, W., Shestopalov, I., Thakar, H., & Gupta, A. O. (2024). Secondary failure of lentiviral vector gene therapy in a cerebral adrenoleukodystrophy patient with an ABCD1 whole-gene deletion. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2024.08.005
Vancouver
Lund TC, Orchard PJ, Nascene DR, King CJ, Braun J, Thakkar S, et al. Secondary failure of lentiviral vector gene therapy in a cerebral adrenoleukodystrophy patient with an ABCD1 whole-gene deletion. Molecular Therapy. 2024. doi:10.1016/j.ymthe.2024.08.005
BibTeX
@article{Lund2024,
author = {Lund, Troy C and Orchard, Paul J and Nascene, David R and King, Carina J and Braun, Jennifer and Thakkar, Stuti and Durose, Willa and Shestopalov, Ilya and Thakar, Himal and Gupta, Ashish O},
title = {Secondary failure of lentiviral vector gene therapy in a cerebral adrenoleukodystrophy patient with an ABCD1 whole-gene deletion},
journal = {Molecular Therapy},
year = {2024},
doi = {10.1016/j.ymthe.2024.08.005}
}
EUVIMED